Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma

Cancer

Volumn 121, Issue 16, 2015, Pages 2720-2729

  Hui, Edwin P ^a   Ma, Brigette B Y ^a   Chan, K C Allen ^a   Chan, Charles M L ^a   Wong, Cesar S C ^b   To, Ka Fai ^a   Chan, Anthony W H ^a   Tung, Stewart Y ^c   Ng, Wai Tong ^d   Cheng, Ashley C ^e   Lee, Victor H F ^f   Chan, Stephen L ^a   Loong, Herbert H F ^a   Kam, Michael K M ^a   Leung, Sing Fai ^a   Ho, Rosalie ^a   Mo, Frankie ^a   Ngan, Roger K C ^g   Chan, Anthony T C ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^c TUEN MUN HOSPITAL   (Hong Kong)

^d PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL   (Hong Kong)

^e PRINCESS MARGARET HOSPITAL   (Hong Kong)

^f QUEEN MARY HOSPITAL   (Hong Kong)

^g QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

biomarker; Epstein Barr virus DNA; ERCC1; nasopharyngeal cancer; single nucleotide polymorphism

Indexed keywords

ADENINE; CISPLATIN; CYTOSINE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; MESSENGER RNA; THYMINE; VIRUS DNA; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CODON; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SAFETY; EPSTEIN BARR VIRUS; ERCC1 GENE; FEMALE; FOLLOW UP; GENE EXPRESSION; GENETIC ASSOCIATION; GENOTYPE; HIGH RISK PATIENT; HONG KONG; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); MUTATIONAL ANALYSIS; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS LOAD; AGED; BLOOD; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; MORTALITY; NASOPHARYNX TUMOR; VIROLOGY;

ADULT; AGED; DNA, VIRAL; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENOTYPE; HERPESVIRUS 4, HUMAN; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES;

EID: 84938744419     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29413     Document Type: Article

References (43)

1. Chan AT, Gregoire V, Lefebvre JL, et al., Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012; 23 (suppl 7): vii83-vii85.
2. Olaussen KA, Dunant A, Fouret P, et al., DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006; 355: 983-991.
3. Gossage L, Madhusudan S., Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev. 2007; 33: 565-577.
4. Vilmar A, Sorensen JB., Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer. 2009; 64: 131-139.
5. Murray D, Macann A, Hanson J, Rosenberg E., ERCC1/ERCC4 5′-endonuclease activity as a determinant of hypoxic cell radiosensitivity. Int J Radiat Biol. 1996; 69: 319-327.
6. Carles J, Monzo M, Amat M, et al., Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with stage I to II head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2006; 66: 1022-1030.
7. Yu JJ, Lee KB, Mu C, et al., Comparison of 2 human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol. 2000; 16: 555-560.
8. Woelfelschneider A, Popanda O, Lilla C, et al., A distinct ERCC1 haplotype is associated with mRNA expression levels in prostate cancer patients. Carcinogenesis. 2008; 29: 1758-1764.
9. Chen P, Wiencke J, Aldape K, et al., Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev. 2000; 9: 843-847.
10. Zhou W, Gurubhagavatula S, Liu G, et al., Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res. 2004; 10: 4939-4943.
11. Isla D, Sarries C, Rosell R, et al., Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol. 2004; 15: 1194-1203.
12. Viguier J, Boige V, Miquel C, et al., ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res. 2005; 11: 6212-6217.
13. Ruzzo A, Graziano F, Loupakis F, et al., Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol. 2007; 25: 1247-1254.
14. Smith S, Su D, Rigault de la Longrais IA, et al., ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol. 2007; 25: 5172-5179.
15. Krivak TC, Darcy KM, Tian C, et al., Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group phase III trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. J Clin Oncol. 2008; 26: 3598-3606.
16. Quintela-Fandino M, Hitt R, Medina PP, et al., DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol. 2006; 24: 4333-4339.
17. Friboulet L, Olaussen KA, Pignon JP, et al., ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med. 2013; 368: 1101-1110.
18. Ma BB, Hui EP, Wong SC, et al., Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma-correlation with excision repair cross-complementing-1 polymorphisms. Ann Oncol. 2009; 20: 1854-1859.
19. Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.
20. Le QT, Zhang Q, Cao H, et al., An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma. Clin Cancer Res. 2013; 19: 2208-2215.
21. Altman DG, McShane LM, Sauerbrei W, Taube SE., Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration [serial online]. BMC Med. 2012; 10: 51.
22. Gaunt TR, Rodriguez S, Day IN., Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool "CubeX" [serial online]. BMC Bioinformatics. 2007; 8: 428.
23. Yin M, Yan J, Voutsina A, et al., No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung Cancer. 2011; 72: 370-377.
24. Huang D, Zhou Y., Nucleotide excision repair gene polymorphisms and prognosis of non-small cell lung cancer patients receiving platinum-based chemotherapy: a meta-analysis based on 44 studies. Biomed Rep. 2014; 2: 452-462.
25. Yang Y, Xian L., The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. Tumour Biol. 2014; 35: 2905-2921.
26. Xu TP, Shen H, Liu LX, Shu YQ., Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports. Gene. 2013; 526: 265-274.
27. Ren S, Zhou S, Wu F, et al., Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy. Lung Cancer. 2012; 75: 102-109.
28. Pierceall WE, Olaussen KA, Rousseau V, et al., Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses. Ann Oncol. 2012; 23: 2245-2252.
29. Vilmar AC, Santoni-Rugiu E, Sorensen JB., ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol. 2010; 21: 1817-1824.
30. Yang ZH, Dai Q, Kong XL, Yang WL, Zhang L., Association of ERCC1 polymorphisms and susceptibility to nasopharyngeal carcinoma. Mol Carcinog. 2009; 48: 196-201.
31. Chang PM, Tzeng CH, Chen PM, et al., ERCC1 codon 118 C>T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma. Cancer Sci. 2009; 100: 278-283.
32. Huang ZH, Hua D, Du X, et al., ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer. World J Gastroenterol. 2008; 14: 6401-6407.
33. Takenaka T, Yano T, Kiyohara C, et al., Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer. 2010; 67: 101-107.
34. Gao R, Reece K, Sissung T, Reed E, Price DK, Figg WD., The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity. Mutat Res. 2011; 708: 21-27.
35. van Huis-Tanja LH, Kweekel DM, Lu X, et al., Excision repair cross-complementation group 1 (ERCC1) C118T SNP does not affect cellular response to oxaliplatin. Mutat Res Fundam Mol Mech Mutagen. 2014; 759: 37-44.
36. Chan SH, Cheung FM, Ng WT, et al., Can the analysis of ERCC1 expression contribute to individualized therapy in nasopharyngeal carcinoma? Int J Radiat Oncol Biol Phys. 2011; 79: 1414-1420.
37. Lee HW, Hwang YH, Han JH, et al., High expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with nasopharyngeal cancer. Oral Oncol. 2010; 46: 209-213.
38. Sun JM, Ahn MJ, Park MJ, et al., Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2011; 80: 655-660.
39. Huang PY, Li Y, Mai HQ, Luo RZ, Cai YC, Zhang L., Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy. Oral Oncol. 2012; 48: 964-968.
40. Jagdis A, Phan T, Klimowicz AC, et al., Assessment of ERCC1 and XPF protein expression using quantitative immunohistochemistry in nasopharyngeal carcinoma patients undergoing curative intent treatment. Int J Radiat Oncol Biol Phys. 2013; 85: 1340-1345.
41. Chen C, Wang F, Wang Z, et al., Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol. 2013; 72: 315-322.
42. Jin H, Xie X, Wang H, et al., ERCC1 Cys8092Ala and XRCC1 Arg399Gln polymorphisms predict progression-free survival after curative radiotherapy for nasopharyngeal carcinoma [serial online]. PLoS One. 2014; 9: e101256.
43. Chan ATC, Ngan RKC, Hui EP, et al., A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) after primary radiotherapy (RT) or chemoradiotherapy (CRT) [abstract]. J Clin Oncol. 2012; 30 (suppl). Abstract 5511.